Early adoption of pharmacogenetic testing for veterans prescribed psychotropic medications

被引：4
作者：
Hull, Leland E. [1 ,2 ]
Chanfreau-Coffinier, Catherine [3 ]
Tuteja, Sony [4 ,5 ]
Berlowitz, Dan [2 ]
Lehmann, Lisa S. [1 ,8 ]
Oslin, David W. [4 ,5 ]
Pyne, Jeffrey M. [6 ]
DuVall, Scott L. [3 ,7 ]
Lynch, Julie A. [2 ,3 ]
机构：
[1] VA Boston Healthcare Syst, Boston, MA 02130 USA
[2] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA 01730 USA
[3] VA Salt Lake City Hlth Care Syst, VA Informat & Comp Infrastruct, Salt Lake City, UT 84148 USA
[4] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[6] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA
[7] Univ Utah, Sch Med, Salt Lake City, UT 84132 USA
[8] Harvard Med Sch, Boston, MA 02115 USA
来源：
PHARMACOGENOMICS | 2019年 / 20卷 / 11期
关键词：
pharmacogenetic testing; psychotropic medications; veterans; MAJOR DEPRESSIVE DISORDER; PHENOCONVERSION; IMPACT;
D O I：
10.2217/pgs-2019-0065
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: Describe the characteristics of providers ordering, patients receiving, and clinical impact of a psychotropic pharmacogenetic test on veteran care. Patients & methods: Observational cohort study linking veterans' laboratory results to electronic health record data. Changes in psychotropic medication prescribing were measured as a function of test results. Results:A total of38 providers tested 181 veterans between10/6/2014 and 2/1/2018. Prescriptions for medications with severe gene-drug interactions decreased; however, 11 such medications were used after testing. For 43 patients, documentation of the results was missing. Conclusion: Most prescribing decisions were congruent with test results, but in a nontrivial number of cases, prescribers appeared not to act on the results. Poor result documentation impeded the potential of results to inform clinical care.
引用
收藏
页码：781 / 789
页数：9
相关论文
共 21 条
  • [1] Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes
    Altar, C. A.
    Carhart, J. M.
    Allen, J. D.
    Hall-Flavin, D. K.
    Dechairo, B. M.
    Winner, J. G.
    [J]. PHARMACOGENOMICS JOURNAL, 2015, 15 (05) : 443 - 451
  • [2] Assurex Health Inc, US DEP VET AFF AW GE
  • [3] Assurex Health Inc, MED 1 TIM COV COMB G
  • [4] The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?
    Dias, Mafalda M.
    Sorich, Michael J.
    Rowland, Andrew
    Wiese, Michael D.
    McKinnon, Ross A.
    [J]. PHARMACEUTICAL RESEARCH, 2017, 34 (08) : 1544 - 1550
  • [5] Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials
    Fabbri, Chiara
    Zohar, Joseph
    Serretti, Alessandro
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2018, 86 : 36 - 44
  • [6] Understanding the pharmacogenetics of selective serotonin reuptake inhibitors
    Fabbri, Chiara
    Minarini, Alessandro
    Niitsu, Tomihisa
    Serretti, Alessandro
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (08) : 1093 - 1118
  • [7] Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
    Greden, John F.
    Parikh, Sagar V.
    Rothschild, Anthony J.
    Thase, Michael E.
    Dunlop, Boadie W.
    DeBattista, Charles
    Conway, Charles R.
    Forester, Brent P.
    Mondimore, Francis M.
    Shelton, Richard C.
    Macaluso, Matthew
    Li, James
    Brown, Krystal
    Gilbert, Alexa
    Burns, Lindsey
    Jablonski, Michael R.
    Dechairo, Bryan
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2019, 111 : 59 - 67
  • [8] Using a pharmacogenomic algorithm to guide the treatment of depression
    Hall-Flavin, D. K.
    Winner, J. G.
    Allen, J. D.
    Jordan, J. J.
    Nesheim, R. S.
    Snyder, K. A.
    Drews, M. S.
    Eisterhold, L. L.
    Biernacka, J. M.
    Mrazek, D. A.
    [J]. TRANSLATIONAL PSYCHIATRY, 2012, 2 : e172 - e172
  • [9] Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting
    Hall-Flavin, Daniel K.
    Winner, Joel G.
    Allen, Josiah D.
    Carhart, Joseph M.
    Proctor, Brian
    Snyder, Karen A.
    Drews, Maureen S.
    Eisterhold, Linda L.
    Geske, Jennifer
    Mrazek, David A.
    [J]. PHARMACOGENETICS AND GENOMICS, 2013, 23 (10) : 535 - 548
  • [10] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
    Hicks, J. K.
    Bishop, J. R.
    Sangkuhl, K.
    Mueller, D. J.
    Ji, Y.
    Leckband, S. G.
    Leeder, J. S.
    Graham, R. L.
    Chiulli, D. L.
    LLerena, A.
    Skaar, T. C.
    Scott, S. A.
    Stingl, J. C.
    Klein, T. E.
    Caudle, K. E.
    Gaedigk, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) : 127 - 134
123